Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Diabetes Care · 01.09.2023 · 46 (9) · 1574-1586
DOI: 10.2337/dci23-0030 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes Care, online erschienen am 25.08.2023. Verfasst von Sandra C Naaman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and American Heart Association Comprehensive Hypertension Center, Univers…. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Heart Failure, Diabetes Mellitus. Die Arbeit wurde bisher 300-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Management of diabetic kidney disease (DKD) has evolved in parallel with our growing understanding of the multiple interrelated pathophysiological mechanisms that involve hemodynamic, metabolic, and inflammatory pathways. These pathways and others play a vital role in the initiation and progression of DKD. Since its initial discovery, the blockade of the renin-angiotensin system has remained a cornerstone of DKD management, leaving a large component of residual risk to be dealt with. The advent of sodium–glucose cotransporter 2 inhibitors followed by nonsteroidal mineralocorticoid receptor antagonists and, to some extent, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has ushered in a resounding paradigm shift that supports a pillared approach in maximizing treatment to reduce outcomes. This pillared approach is like that derived from the approach to heart failure treatment. The approach mandates that all agents that have been shown in clinical trials to reduce cardiovascular outcomes and/or mortality to a greater extent than a single drug class alone should be used in combination. In this way, each drug class focuses on a specific aspect of the disease's pathophysiology. Thus, in heart failure, β-blockers, sacubitril/valsartan, a mineralocorticoid receptor antagonist, and a diuretic are used together. In this article, we review the evolution of the pillar concept of therapy as it applies to DKD and discuss how it should be used based on the outcome evidence. We also discuss the exciting possibility that GLP-1 RAs may be an additional pillar in the quest to further slow kidney disease progression in diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, IL.
ORCID-Profile: George L Bakris
Förderung
- NIDDK NIH HHS
Zitieren
APA
Naaman, S. C., & Bakris, G. L. (2023). Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care, 46(9), 1574-1586. https://doi.org/10.2337/dci23-0030
Vancouver
Naaman SC, Bakris GL. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care. 2023;46(9):1574-1586. doi:10.2337/dci23-0030
BibTeX
@article{Naaman2023,
author = {Naaman, Sandra C and Bakris, George L},
title = {Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression},
journal = {Diabetes Care},
year = {2023},
volume = {46},
number = {9},
pages = {1574--1586},
doi = {10.2337/dci23-0030}
}
EUVIMED